Showing 4221-4230 of 5558 results for "".
- Ipsen's Dysport Approved for Use in Canadahttps://practicaldermatology.com/news/20130418-ipsens_dysport_approved_for_use_in_canada/2459560/Health Canada granted a marketing authorization for Dysport (Botulinum toxin type A for injection) for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) in adult patients younger than 65 years of age. Medicis Aesthetics Canada, a division of Valeant Phar
- World's Most Valuable Cosmetics Brands Revealedhttps://practicaldermatology.com/news/20130410-worlds_most_valuable_cosmetics_brands_revealed/2459566/Brand Finance released its annual study of the top 50 most valuable cosmetics brands. Despite a very slight brand value fall, Olay holds its dominant position at the top of the BrandFinance Cosmetics 50 table, with a value of US$11.7 billion. However, Olay's lead at the top has shrunk from US$4 bill
- La Roche-Posay Contributes to The Mollie Biggane Melanoma Foundationhttps://practicaldermatology.com/news/20130203-la_roche-posay_contributes_to_the_mollie_biggane_melanoma_foundation/2459621/As part of their continued efforts towards sun safety education and awareness, La Roche-Posay is partnering with Mollie's Fund for the second year in a row. To honor the life of Mollie Biggane – a college sophomore who tragically passed away from melanoma a
- Grassley Urges White House to Finish Sunshine Act Regulationshttps://practicaldermatology.com/news/20130125-grassley_urges_white_house_to_finish_sunshine_act_regulations/2459625/Sen. Chuck Grassley of Iowa today urged the White House to finalize the Physician Payments Sunshine Act regulations that will disclose the financial relationships between drug and medical device companies and doctors. “Congress designed the law so that the data would be publicly available by Sept.
- Results Released from Phase 2 Trial of IMO-3100 in Plaque Psoriasishttps://practicaldermatology.com/news/20121219-results_released_from_phase_2_trial_of_imo-3100_in_plaque_psoriasis/2459655/In a recent study, Idera Pharmaceuticals reported that 48 percent of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in
- Jurlique Purely Bright Releases Clinical Resultshttps://practicaldermatology.com/news/20121128-jurlique_purely_bright_releases_clinical_results/2459672/Jurlique Purely Bright, a brightening system launched earlier this year, released clinical results on its product line. After 30 days, the system was clinically proven to help reduce dark spots. After 12 weeks, skin surface smoothness doubled at
- Syneron Kicks Off New Campaignhttps://practicaldermatology.com/news/20121002-syneron_kicks_off_new_campaign/2459721/Syneron Medical Ltd. launched a new Break Up. Get Even! campaign for its elure product line. As part of the campaign, five winners will receive a complete elure range of products ($335 value) to “break up” stubborn discoloration and “get even” skin tone. The campaign is run through the company's
- NeoStrata Teams with Avon on Anew Clinical Pro Line Eraserhttps://practicaldermatology.com/news/20120917-neostrata_teams_with_avon_on_anew_clinical_pro_line_eraser/2459739/In collaboration with NeoStrata Company,
- App Launched for Medical Entrepreneurshttps://practicaldermatology.com/news/20120824-app_launched_for_medical_entrepreneurs/2459746/The free Medical Entrepreneur App went live on the Apple Store this month. The app, developed by Steven M. Hacker, MD, provides healthcare providers and medical students with business intelligence and decision making tools before, duri
- FDA Extends Action Date For Tofacitinib New Drug Application By Three Monthshttps://practicaldermatology.com/news/20120824-us_food_and_drug_administration_extends_action_date_for_tofacitinib_new_drug_application_by_three_months/2459748/